In our analysis, patients on GLP‐1 RAs had a statistically significant decrease in RR of MACE in both subgroups of patients with type 2 diabetes (RR 0.88, 95% CI 0.81−0.96) and overweight/obese patients (RR 0.81, 95% CI 0.74−0.88) compared with placebo (overall population: RR 0.87, 95% CI 0.82−0.93, I2 = 28%, p = 0.0005) (Figure 3A). Here, GLP1R is linked to type 2 diabetes mellitus.